The Impact of GLP-1 Receptor Agonists on Body Composition and Musculoskeletal Integrity: A Review of Mechanisms, Protective Strategies, and Clinical Perspectives
DOI:
https://doi.org/10.12775/QS.2026.53.69771Keywords
GLP-1 receptor agonists, body composition, muscle mass, resistance training, sarcopenia, myosteatosis, obesity, bone mineral density, metabolic syndromeAbstract
The emergence of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GIP/GLP-1 agonists has revolutionized obesity pharmacotherapy, enabling weight loss magnitudes of 15–20%, previously attainable primarily through bariatric surgery. A significant clinical challenge, however, is the "muscle gap"—the substantial loss of lean body mass (LBM) observed in pivotal trials. This review provides a critical analysis of the impact of incretin-based therapies on tissue composition, skeletal muscle quality, and functional performance. Drawing on the latest clinical and molecular evidence, we demonstrate that the influence of GLP-1 RAs on skeletal muscle is multidimensional. While absolute muscle mass typically decreases, advanced imaging data suggest an improvement in metabolic muscle "quality" through the reduction of intramuscular fat infiltration and enhanced capillary perfusion. This paper emphasizes that structured exercise - particularly resistance training - and nutritional optimization are not merely supportive measures but essential foundations of therapy required to maintain functional strength and prevent iatrogenic sarcopenia. The review further explores the unique osteoprotective effects of GLP-1 RAs, which safeguard bone mineral density during rapid weight loss, and discusses emerging pharmacological frontiers, including co-pharmacotherapy with myostatin inhibitors and triple agonists like retatrutide. Longitudinal insights from the S-LiTE trial indicate that the sustainability of metabolic benefits post-treatment is heavily dependent on exercise-induced adaptations. We conclude that optimal obesity management requires a multidisciplinary approach where pharmacotherapy serves as an adjunct to structured lifestyle changes, prioritizing functional fitness and long-term musculoskeletal health.References
1. Conte, C., Hall, K. D., & Klein, S. (2024). Is Weight Loss-Induced Muscle Mass Loss Clinically Relevant?. JAMA, 332(1), 9–10. https://doi.org/10.1001/jama.2024.6586
2. Rossi, G., Bucciarelli, L., Mananguite, C. L., Giovarelli, M., & Fiorina, P. (2026). Muscle loss and GLP-1R agonists use. Acta diabetologica, 63(2), 333–342. https://doi.org/10.1007/s00592-025-02611-2
3. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., & STEP 1 Study Group (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
4. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., Stefanski, A., & SURMOUNT-1 Investigators (2022). Tirzepatide Once Weekly for the Treatment of Obesity. The New England journal of medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038.
5. Neeland, I. J., Marso, S. P., Ayers, C. R., Lewis, B., Oslica, R., Francis, W., Rodder, S., Pandey, A., & Joshi, P. H. (2021). Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial. The lancet. Diabetes & endocrinology, 9(9), 595–605. https://doi.org/10.1016/S2213-8587(21)00179-0
6. Lundgren, J. R., Janus, C., Jensen, S. B. K., Juhl, C. R., Olsen, L. M., Christensen, R. M., Svane, M. S., Bandholm, T., Bojsen-Møller, K. N., Blond, M. B., Jensen, J. B., Stallknecht, B. M., Holst, J. J., Madsbad, S., & Torekov, S. S. (2021). Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. The New England journal of medicine, 384(18), 1719–1730. https://doi.org/10.1056/NEJMoa2028198
7. Codella, R., Senesi, P., & Luzi, L. (2025). GLP-1 agonists and exercise: the future of lifestyle prioritization. Frontiers in clinical diabetes and healthcare, 6, 1720794. https://doi.org/10.3389/fcdhc.2025.1720794
8. Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017). Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, obesity & metabolism, 19(9), 1242–1251. https://doi.org/10.1111/dom.12932
9. Tinsley, G. M., & Nadolsky, S. (2025). Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series. SAGE open medical case reports, 13, 2050313X251388724. https://doi.org/10.1177/2050313X251388724
10. Sattar, N., Neeland, I. J., Dahlqvist Leinhard, O., Fernández Landó, L., Bray, R., Linge, J., & Rodriguez, A. (2025). Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial. The lancet. Diabetes & endocrinology, 13(6), 482–493. https://doi.org/10.1016/S2213-8587(25)00027-0
11. Alissou, M., Demangeat, T., Folope, V., Van Elslande, H., Lelandais, H., Blanchemaison, J., Cailleaux, P. E., Guney, S., Aupetit, A., Aubourg, A., Rapp, C., Petit, A., Godin, M., Vignal, L., Grigioni, S., Déchelotte, P., Colange, G., Coëffier, M., & Achamrah, N. (2026). Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study. Diabetes, obesity & metabolism, 28(1), 112–121. https://doi.org/10.1111/dom.70141
12. Anyiam, O., Ardavani, A., Rashid, R. S. A., Panesar, A., & Idris, I. (2025). How do glucagon-like Peptide-1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: A systematic review and meta-analysis. Obesity reviews : an official journal of the International Association for the Study of Obesity, 26(7), e13916. https://doi.org/10.1111/obr.13916
13. Wang, T., Zhou, D., & Hong, Z. (2025). Sarcopenia and cachexia: molecular mechanisms and therapeutic interventions. MedComm, 6(1), e70030. https://doi.org/10.1002/mco2.70030
14. Coskun, T., Wu, Q., Schloot, N. C., Haupt, A., Milicevic, Z., Khouli, C., & Harris, C. (2025). Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The lancet. Diabetes & endocrinology, 13(8), 674–684. https://doi.org/10.1016/S2213-8587(25)00092-0
15. Mastaitis, J.W., Gomez, D., Raya, J.G. et al. GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates. Nat Commun 16, 4377 (2025). https://doi.org/10.1038/s41467-025-59485-9
16. Old, V. J., Davies, M. J., Papamargaritis, D., Choudhary, P., & Watson, E. L. (2025). The Effects of Glucagon-Like Peptide-1 Receptor Agonists on Mitochondrial Function Within Skeletal Muscle: A Systematic Review. Journal of cachexia, sarcopenia and muscle, 16(1), e13677. https://doi.org/10.1002/jcsm.13677
17. Ren, Q., Zhi, L., & Liu, H. (2025). Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study. Drug design, development and therapy, 19, 5645–5652. https://doi.org/10.2147/DDDT.S531778
18. The Lancet Diabetes Endocrinology (2025). The era of GLP-1 receptor agonists: costs versus benefits. The lancet. Diabetes & endocrinology, 13(1), 1. https://doi.org/10.1016/S2213-8587(24)00376-0
19. Jensen, S. B. K., Blond, M. B., Sandsdal, R. M., Olsen, L. M., Juhl, C. R., Lundgren, J. R., Janus, C., Stallknecht, B. M., Holst, J. J., Madsbad, S., & Torekov, S. S. (2024). Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. EClinicalMedicine, 69, 102475. https://doi.org/10.1016/j.eclinm.2024.102475
20. Sandsdal, R. M., Juhl, C. R., Jensen, S. B. K., Lundgren, J. R., Janus, C., Blond, M. B., Rosenkilde, M., Bogh, A. F., Gliemann, L., Jensen, J. B., Antoniades, C., Stallknecht, B. M., Holst, J. J., Madsbad, S., & Torekov, S. S. (2023). Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial. Cardiovascular diabetology, 22(1), 41. https://doi.org/10.1186/s12933-023-01765-z
21. Wang, T., Zhou, D., & Hong, Z. (2025). Sarcopenia and cachexia: molecular mechanisms and therapeutic interventions. MedComm, 6(1), e70030. https://doi.org/10.1002/mco2.70030
22. Iepsen, E. W., Lundgren, J. R., Hartmann, B., Pedersen, O., Hansen, T., Jørgensen, N. R., Jensen, J. E., Holst, J. J., Madsbad, S., & Torekov, S. S. (2015). GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women. The Journal of clinical endocrinology and metabolism, 100(8), 2909–2917. https://doi.org/10.1210/jc.2015-1176
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Szymon Domagała, Zuzanna Wiater, Aleksandra Włodarczyk, Karolina Brankowska, Marta Jakubowska, Michał Olejnik, Paulina Tymińska, Piotr Artur Górka, Julia Frączek, Witold Kądziołka
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 8
Number of citations: 0
